Scientific researchers using both human and animal models have suggested the B7-33 may have the following clinical applications:
Treatment for Fibrosis
B7-33 peptide shows strong potential in treating fibrosis by selectively activating the relaxin receptor RXFP1, which regulates tissue remodelling and repair. It inhibits TGF-β signalling, a major driver of fibrosis, preventing excessive collagen build up and scar tissue formation in organs like the heart, lungs, liver, and kidneys [2]. Additionally, B7-33 enhances nitric oxide (NO) production, improving blood flow and reducing inflammation, further limiting fibrotic progression. Unlike traditional therapies, B7-33 targets fibrosis at its source while minimizing side effects, making it a promising candidate for treating cardiac, pulmonary, and organ fibrosis in various chronic conditions [3].
Cardiovascular Protection
B7-33 peptide hormone offers significant cardiovascular protection by targeting the relaxin receptor RXFP1, which plays a key role in vasodilation, anti-fibrotic activity, and heart function. One of its primary mechanisms is the stimulation of nitric oxide (NO) production, which relaxes blood vessels, improves circulation, and helps lower blood pressure, reducing strain on the heart [3].
Additionally, in vitro testing has shown that B7-33 inhibits TGF-β signalling, preventing cardiac fibrosis—a condition where excessive collagen build up stiffens the heart muscle, leading to heart failure and reduced cardiac efficiency. By reducing inflammation and oxidative stress, B7-33 helps maintain healthy heart tissue, improving overall cardiovascular function [4].
Unlike traditional relaxin-based therapies, B7-33 is designed to target beneficial cardiovascular pathways with fewer systemic side effects. Its ability to support vascular health, prevent fibrosis, and enhance cardiac function makes it a promising candidate for treating hypertension, heart failure, and other cardiovascular diseases. Research continues to explore its full therapeutic potential.
Anti-Inflammatory
B7-33 peptide exhibits potent anti-inflammatory properties by selectively activating the relaxin receptor RXFP1, which regulates immune responses and tissue repair. One of its key mechanisms is the inhibition of pro-inflammatory cytokines, such as TNF-α and IL-6, which contribute to chronic inflammation and tissue damage [3]. By suppressing these inflammatory signals, B7-33 helps protect organs from fibrotic and degenerative diseases.
Additionally, B7-33 reduces TGF-β signalling, a major driver of inflammation-induced fibrosis, preventing excessive scar tissue formation in the heart, lungs, liver, and kidneys. It also enhances nitric oxide (NO) production, which helps regulate immune function and improves vascular health [5].
Unlike conventional anti-inflammatory drugs, B7-33 does not merely block inflammation but modulates the body’s natural healing processes, promoting balanced immune responses. This makes it a promising therapy for conditions like pulmonary fibrosis, heart disease, arthritis, and other chronic inflammatory disorders. Research continues to explore its full therapeutic potential.
Wound Healing and Tissue Regeneration
B7-33 peptide promotes wound healing and tissue regeneration by activating the relaxin receptor RXFP1, which enhances cell repair, reduces fibrosis, and improves blood flow. It inhibits TGF-β signalling, preventing excessive scar tissue formation while supporting the remodelling of the extracellular matrix. Additionally, B7-33 stimulates nitric oxide (NO) production, leading to better oxygenation and nutrient delivery to damaged tissues. Its anti-inflammatory properties further aid in reducing swelling and accelerating recovery. By promoting healthy tissue regeneration rather than excessive scarring, B7-33 is a promising candidate for wound healing, surgical recovery, and regenerative medicine applications [6].
PharmaLabGlobal supplies Peptide Pen Kits, supplied with pre-mixed peptide cartridges, no peptide reconstitution required. Buy B7-33 Pre-Mixed Peptide Pen.
